Përshkrimi i kompanisë
Our commitment to research, development and the production of biopharmaceutical products.
Dompé is active in Primary Care, producing prescription drugs and over the counter (OTC) medicines, dietary supplements, medical devices and cosmetics.
We are also committed to finding innovative solutions for the treatment of rare diseases where a new therapy can provide a significant improvement over the current standard of care.
Dompé’s Cenegermin Nerve Growth Factor-based therapy was awarded Breakthrough Therapy designation by the US Food and Drug Administration (FDA) and marketing authorized by the FDA in August 2018 and by the European Medicines Agency (EMA) in July 2017.
Punët aktive nga Dompe Albania shpk